Androgen Receptor Degrader Combinations for Triple-Negative Breast Cancer
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Current treatments for triple negative breast cancer (TNBC) have limited therapeutic efficacy, and there is a need for new approaches that target the androgen receptor (AR) signaling pathway, which has not been previously explored in TNBC treatment.
Innovation Solution
The use of AR degraders, specifically proteolysis-targeting chimeras (PROTACs), in combination with PI3Kα inhibitors, PARP inhibitors, immunotherapeutic drugs, or chemotherapeutic drugs like Paclitaxel, to degrade androgen receptors, offering a novel therapeutic strategy for TNBC.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If chemotherapy drugs (cyclophosphamide, doxorubicin, 5-FU, paclitaxel, cisplatin) are used to treat TNBC, then the treatment covers standard clinical options, but the therapeutic efficacy is insufficient
Solution Approach 1:
The patent segments the treatment approach by introducing a novel mechanism (PROTAC-mediated protein degradation) separate from traditional chemotherapy, allowing simultaneous use of both approaches to achieve synergistic effects and overcome treatment resistance
Solution Approach 2:
The patent combines chemically distinct entities (PROTAC molecules comprising ligand A, linker, and ligand B) into composite structures that enable dual functionality: binding to the target protein and recruiting E3 ubiquitin ligase for degradation
2Adaptability or versatility
If AR PROTACs are used to degrade androgen receptors, then a novel mechanism is introduced for TNBC treatment, but the combination with existing drugs requires optimization
Solution Approach 1:
The patent systematically varies key parameters including PROTAC molecular structure (different linkers and ligands), drug combination ratios, and dosing schedules to optimize therapeutic efficacy while managing combination complexity
Solution Approach 2:
The patent designs PROTAC molecules with universal applicability across different TNBC contexts by targeting the androgen receptor pathway, which can be combined with multiple existing drug classes (chemotherapy, targeted therapy, immunotherapy) rather than requiring drug-specific optimizations
Applied Scientific Principles
This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.
Function Achieved in This Case
The combination of AR degraders with targeted or chemotherapeutic drugs demonstrates synergistic effects in inhibiting TNBC cell proliferation, providing a promising treatment option for TNBC, including AR-positive cases, with potential for improved clinical outcomes.
Implementation Method 1
The obtained small molecule probe can simultaneously bind to the target protein and E3 ubiquitin ligases, thereby promoting the ubiquitination of the target protein, by which the protein can be recognized and degraded by the proteasome
Implementation Method 2
the protein can be recognized and degraded by the proteasome
Data Source
Figure 1~3
Figure 4~6
Figure 7~9
AI summary
A combination drug for treating triple-negative breast cancer. Androgen receptor-targeting degraders (including PROTACs) can effectively prevent and/or treat triple negative breast cancer (including androgen receptor-positive triple negative breast cancer). The combined use of an androgen receptor degrader and a targeting drug (including PI3Kα inhibitors and PARP inhibitors), immunotherapy drug or chemotherapy drug can effectively prevent and/or treat triple negative breast cancer.